Epithelial Ovarian Cancer Clinical Trial
Official title:
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer
Verified date | October 2021 |
Source | Shanghai East Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a prospective, single-arm, open-label, single-dose dose finding and extension study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the LCAR-M23 CAR-T cell therapy in subjects with relapsed and refractory epithelial ovarian cancer after prior adequate standard of care.
Status | Terminated |
Enrollment | 15 |
Est. completion date | June 7, 2022 |
Est. primary completion date | June 7, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. The subjects have been fully informed of the possible risks and benefits of participating in this study and have voluntarily signed the informed consent form (ICF) 2. Age: 18-70 years (including 18 and 70 years) 3. Female subjects with histologically or cytologically confirmed advanced epithelial ovarian cancer including fallopian tube and primary peritoneal cancers 4. Mesothelin (MSLN) positive 5. Prior adequate standard of care, treatment failure or intolerance. 6. Imaging shows an evaluable tumor lesion 7. ECOG 0-1 8. Expected survival = 3 months Exclusion Criteria: 1. Patients who have received the following anti-tumor treatments prior to apheresis: - Cytotoxic therapy within 14 days - Small molecule targeted therapy within 14 days or at least 5 half-lives, whichever is shorter - Therapy with monoclonal antibody within 21 days - Immunomodulatory therapy within 7 days - Radiotherapy within 14 days and endocrine therapy within 14 days (including tamoxifen, aromatase inhibitor, high-potency progesterone and gonadotropin-releasing hormone analogue, etc.) 2. Previously treated with CAR-T/TCR-T cell therapy against any target or other cell therapies or therapeutic tumor vaccine 3. Previously treated with any MSLN-targeted therapy 4. Brain metastases with central nervous system symptoms 5. Pregnant or lactating women 6. Any condition in which, in the opinion of the investigator, the subject is ineligible for participation in the study |
Country | Name | City | State |
---|---|---|---|
China | Shanghai East Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai East Hospital | Anhui Provincial Hospital, East Clinical Center of Oncology, Nanjing Legend Biotech Co. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose-limiting toxicity (DLT) and incidence, severity, and type of treatment-emergent adverse events (TEAEs) | Dose-limiting toxicity (DLT) refers to a drug-related toxicity during treatment with the drug, the severity of which is clinically unacceptable, limiting the further escalation of drug dose. An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment. | 90 days post infusion | |
Primary | MTD/ RP2D regimen finding | Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) | 90 days post infusion | |
Primary | Chimeric Antigen Receptor T (CAR-T) Positive Cell Concentration | Venous blood samples will be collected for measurement of CAR-T positive cellular concentration | 2 years post infusion | |
Secondary | Disease control rate (DCR) after administration | Disease Control Rate (DCR) is defined as the proportion of patients with complete response, partial response and stable disease. | 2 years post infusion | |
Secondary | Objective Response Rate (ORR) after administration | Objective Response Rate (ORR) is defined as the proportion of subjects who achieve CR or PR after treatment via LCAR-M23 cell infusion, and the objective tumor response rate will be calculated for patients with measurable disease as per RECIST 1.1 criteria only. | 2 years post infusion | |
Secondary | Time to Response (TTR) after administration | Time to Response (TTR) is defined as the time interval from the date of first infusion of LCAR-M23 cell formulation to the date of the first response evaluation of the subject who has met all criteria for PR or better. | 2 years post infusion | |
Secondary | Duration of Response (DOR) after administration | Duration of Response (DOR) is defined as the time from the first documentation of response (PR or better) to the first documentation of disease progression evidence (as per RECIST 1.1 criteria) of the responders (who achieve PR or better response). | 2 years post infusion | |
Secondary | Progress Free Survival (PFS) after administration | Progression Free Survival (PFS) is defined as the time interval from the date of first infusion of LCAR-M23 cell formulation to the first documentation of disease progression (as per RECIST 1.1 criteria) or death (due to any cause), whichever occurs first. | 2 years post infusion | |
Secondary | Overall Survival (OS) after administration | Overall survival (OS) is defined as the time interval from the date of first infusion of LCAR-M23 cell formulation to death of the subject. | 2 years post infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03393884 -
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05200559 -
T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT04546373 -
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
|
||
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Completed |
NCT01442051 -
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer
|
N/A | |
Not yet recruiting |
NCT04983550 -
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
|
Phase 2 | |
Completed |
NCT02480374 -
Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT01680575 -
Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer
|
N/A | |
Terminated |
NCT01202890 -
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
|
Phase 1 | |
Completed |
NCT00561795 -
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
|
Phase 2 | |
Completed |
NCT00314678 -
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04889495 -
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
|
||
Not yet recruiting |
NCT06010667 -
A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
|
||
Recruiting |
NCT06085456 -
Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study
|
||
Completed |
NCT06366997 -
Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test
|
||
Active, not recruiting |
NCT05212779 -
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
|
||
Recruiting |
NCT04620954 -
Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
|
Phase 1/Phase 2 | |
Completed |
NCT02312661 -
Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer
|
Phase 1 | |
Completed |
NCT01666444 -
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT01891344 -
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
|
Phase 2 |